Pfizer’s Paxlovid to Face FDA Advisory Panel Meeting on March 16

Pfizer Inc.’s Covid-19 therapy Paxlovid will face a panel of FDA advisers on March 16 as the drugmaker seeks full approval for the pill, according to an FDA filing.

• The meeting is to discuss the company’s new drug application for Paxlovid, for the proposed indication of treating mild-to-moderate Covid-19 for adults who are at high risk of having a more severe form of the disease, including hospitalization or death
• Paxlovid is currently available under an emergency-use authorization

To contact the reporters on this story:
Bre Bradham in New York at bbradham@bloomberg.net;
Jeremy R. Cooke in Mount Pleasant, SC ...